Name: Levofloxacin
Brand: Selleck Chemicals
SKU: S1940
Availability: InStock
Rating: 5 (8 reviews)

Jump to

Quality Control

Batch: Purity: 99.91%

99.91

Related Targets	HDAC PARP ATM/ATR DNA-PK WRN DNA/RNA Synthesis PPAR Sirtuin Casein Kinase eIF
Other Topoisomerase Inhibitors	Camptothecin (CPT) Betulinic acid (S)-10-Hydroxycamptothecin Beta-Lapachone Ellagic acid Amonafide Voreloxin (SNS-595) hydrochloride Hydroxy Camptothecine Cu(II)-Elesclomol Genz-644282

Cell Culture, Treatment & Working Concentration

Cell Lines	Assay Type	Concentration	Incubation Time	Activity Description
HEK293 cells	Function assay		1.5 mins	Inhibition of human MATE1-mediated ASP+ uptake expressed in HEK293 cells after 1.5 mins by fluorescence assay, IC50=17.9 μM
human 5637 cells	Function assay	200 to 300 ug/ml	12 h	Antibacterial activity against uropathogenic Escherichia coli UTI89 infected in human 5637 cells assessed as decrease in intracellular bacterial level at 200 to 300 ug/ml after 12 hrs by serial dilution method
Click to View More Cell Line Experimental Data

Solubility

In vitro
Batch:

DMSO : 18 mg/mL (49.81 mM)
(Moisture-contaminated DMSO may reduce solubility. Use fresh, anhydrous DMSO.)

Water : 18 mg/mL

Ethanol : 2 mg/mL

Molarity Calculator

Mass	Concentration	Volume	Molecular Weight
Mass value Mass unit	Concentration value Concentration unit	Volume value Volume unit	Molecular weight (g/mol)

Dilution Calculator Molecular Weight Calculator

In vivo batch selection In vivo Batch:
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
Clear solution	5%DMSO 1 40%PEG300 2 5%Tween80 3 50%ddH2O Validated by Selleck labs. Should you need adjustments to this formulation, contact our sales team for custom testing.	0.900mg/ml (2.49mM)	Taking the 1 mL working solution as an example, add 50 μL of 18 mg/ml clarified DMSO stock solution to 400 μL of PEG300, mix evenly to clarify it; add 50 μL of Tween80 to the above system, mix evenly to clarify; then continue to add 500 μL of ddH2O to adjust the volume to 1 mL. The mixed solution should be used immediately for optimal results.
Clear solution	5% DMSO 1 95% Corn oil Validated by Selleck labs. Should you need adjustments to this formulation, contact our sales team for custom testing.	0.450mg/ml (1.25mM)	Taking the 1 mL working solution as an example, add 50 μL of 9 mg/ml clear DMSO stock solution to 950 μL of corn oil and mix evenly. The mixed solution should be used immediately for optimal results.
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage: mg/kg

Average weight of animals: g

Dosing volume per animal: μL

Number of animals:

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO

%

% Tween 80

% ddH₂O

% DMSO

+

%

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH₂O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Chemical Information, Storage & Stability

Molecular Weight	361.37	Formula	C₁₈H₂₀FN₃O₄	Storage (From the date of receipt)	3 years-20°Cpowder
CAS No.	100986-85-4	Download SDF		Storage of Stock Solutions	1 year-80°Cin solvent 1 month-20°Cin solvent
Synonyms	Fluoroquinolone			SMILES	CC1COC2=C3N1C=C(C(=O)C3=CC(=C2N4CCN(CC4)C)F)C(=O)O

Read more about storage stability stock solution CAS number SMILES

Mechanism of Action

Targets/IC₅₀/Ki	Topoisomerase II Topoisomerase IV
In vitro	Levofloxacin is active against most aerobic Gram-positive and Gram-negative organisms and demonstrates moderate activity against anaerobes. This compound is two-fold more active than ciprofloxacin against Streptococcus pneumoniae and 2- to 4-fold more active than ciprofloxacin against Staphylococcus aureus, Xanthomonas maltophilia, and Bacteroides fragilis. It is two- to eightfold more active than ciprofloxacin against coagulase-negative staphylococci and Acinetobacter spp., although these improvements in potency may not be clinically relevant. This agent inhibits 90% of streptococci when it is used at concentrations of 1 mg/mL to 2 mg/mL. It exhibits twofold greater inhibitory and bactericidal activities than ofloxacin against either extracellular or intracellular tubercle bacilli. This compound has the least inhibitory effect on osteoblastic cell growth, with a 50% inhibitory concentration of approximately 80 mg/mL at 48 and 72 hours. It results in strong inhibition of calcium deposition, as determined on day 14 by alizarin red staining and biochemical analysis. It inhibits glycosaminoglycan synthesis initially and DNA synthesis and mitochondrial function secondarily at actual arthropathic concentrations in cultured rabbit chondrocytes but that these changes are reversible and not enough to kill the cells.
In vivo	Levofloxacin is as efficacious as or more efficacious than that with ciprofloxacin in systemic as well as pyelonephritis infections in mice. This compound achieves higher concentrations in the serum and tissue of mice than does ciprofloxacin.
References	[1] https://pubmed.ncbi.nlm.nih.gov/7516863/ [2] https://pubmed.ncbi.nlm.nih.gov/1503449/ [3] https://pubmed.ncbi.nlm.nih.gov/8067756/ [4] https://pubmed.ncbi.nlm.nih.gov/11117292/ [5] https://pubmed.ncbi.nlm.nih.gov/8540702/

Clinical Trial Information

(data from https://clinicaltrials.gov, updated on 2026-06-30)

NCT Number	Recruitment	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT07675954	NOT_YET_RECRUITING	Rifampicin-Resistant Tuberculosis	Seoul National University Hospital	2026-10-01	PHASE3
NCT06810583	RECRUITING	Leukemia; Acute Myeloid Leukemia; Lymphoblastic Leukemia in Children	St. Jude Children's Research Hospital	2025-05-22	PHASE1
NCT07585461	NOT_YET_RECRUITING	Opportunistic Infections, HIV Related; Disseminated Mycobacterium Avium Complex Infection	Shanghai Public Health Clinical Center	2026-04-30
NCT07788404	RECRUITING	Prosthetic Joint Infection; Osteomyelitis; Staphylococcal Infections	Groupe Hospitalier Diaconesses Croix Saint-Simon	2023-06-10
NCT06494072	RECRUITING	Community Acquired Pneumonia in Children	Medical College of Wisconsin	2024-08-22	PHASE4
NCT07528417	NOT_YET_RECRUITING	Myeldysplastic Syndrome (MDS); MYELOPROLIFERATIVE DISORDER (P Vera, CMML, ET); Acute Myeloid Leukemia	University of Manitoba	2026-09-01	PHASE2

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Levofloxacin Topoisomerase inhibitor

Chemical Structure

Molecular Weight: 361.37